Abstract Details
|
Victoria Smith
PRESENTER |
No disclosure on file |
| No disclosure on file | |
| Kevin Patel, MD | No disclosure on file |
| Wendy Gabel (Biogen, Inc.) | No disclosure on file |
| Glenn A. Phillips, PhD | Dr. Phillips has received personal compensation for serving as an employee of argenx. Dr. Phillips has stock in argenx. |
| No disclosure on file | |
| Eric Klawiter, MD, FAAN (Massachusetts General Hospital) | Dr. Klawiter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Galen/Atlantica. Dr. Klawiter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Klawiter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Banner Life Sciences. Dr. Klawiter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Greenwich Biosciences. Dr. Klawiter has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for OM1. Dr. Klawiter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. The institution of Dr. Klawiter has received research support from Biogen. The institution of Dr. Klawiter has received research support from Abbvie. The institution of Dr. Klawiter has received research support from Genentech. |